Onpattro 2 mg/mL concentrate for solution for infusion.
Sponsors
Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc.
Conditions
Hereditary Transthyretin AmyloidosisTransthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Phase 3
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
CompletedCTIS2023-508365-33-00
Start: 2019-04-09End: 2025-07-17Target: 44Updated: 2025-02-25
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
CompletedCTIS2023-508364-29-00
Start: 2019-11-22End: 2025-05-15Target: 79Updated: 2025-08-14